EXPA32 Antibody

What methodologies are most effective for isolating novel neutralizing antibodies from infected individuals?

Isolation of potent neutralizing antibodies from infected individuals typically follows a systematic process that begins with careful donor selection. For example, in the case of Epstein-Barr virus (EBV) research, scientists successfully isolated gH/gL-specific antibodies like 1D8 from infected individuals, though these were found to be quite rare .

The methodology generally involves:

• Collection of peripheral blood mononuclear cells (PBMCs) from infected individuals

• Isolation and immortalization of memory B cells

• Screening of B cell supernatants for binding to target antigens

• Single-cell sorting of antigen-specific B cells

• Recovery of antibody heavy and light chain variable regions through RT-PCR

• Cloning into expression vectors containing human IgG1 constant regions

• Recombinant expression in 293F cells or similar expression systems

• Purification via Protein A affinity chromatography and size exclusion chromatography

The rarity of potent neutralizing antibodies necessitates screening large numbers of memory B cells. In the case of anti-EBV antibodies like 1D8, AMMO1, and 769B10, these were isolated at a very low frequency, underscoring the challenge in identifying such antibodies .

How do researchers evaluate the neutralization potential of newly isolated antibodies?

Comprehensive evaluation of neutralizing antibodies requires a multi-faceted approach:

• In vitro neutralization assays: Testing the antibody's ability to block infection in relevant cell types. For instance, with EBV antibodies, efficacy must be tested against both B cells and epithelial cells, the two major targets for infection .

• Binding kinetics assessment: Using surface plasmon resonance (SPR) or biolayer interferometry (BLI) to determine binding affinity (KD values) and on/off rates.

• Epitope mapping: Through crystallography, cryo-electron microscopy, or mutational analysis to identify the precise binding site, as was done with 1D8 binding to the D-I/D-II domains of EBV gH/gL .

• Functional inhibition assays: Assessing whether the antibody blocks specific virus-host interactions, such as the 1D8 antibody's ability to inhibit viral membrane fusion and gH/gL binding to the epithelial cell receptor EphA2 .

• In vivo protection studies: Using appropriate animal models, such as humanized mice, to evaluate whether the antibody provides protection against viral challenge and reduces viral loads and associated pathology .

What structural determinants enable antibodies to neutralize viral infection across multiple cell types?

The ability of antibodies to neutralize virus infection in multiple cell types depends on their targeting of critical viral components involved in entry across different cell types. For EBV, which has distinct entry mechanisms for B cells and epithelial cells, this is particularly relevant.

Structural studies of the 1D8 antibody revealed that it binds to a key vulnerable interface between the D-I/D-II domains of the viral gH/gL protein, especially the D-II of gH . This binding:

• Interferes with gH/gL-mediated membrane fusion, a process required for entry into both B cells and epithelial cells

• Inhibits gH/gL binding to epithelial cell receptor EphA2

• Targets a region that is critical for the viral fusion machinery regardless of the cell type

Importantly, the epitope recognized by 1D8 is located on the opposite side of that recognized by other neutralizing antibodies like AMMO1, CL40, and 769B10, suggesting multiple vulnerable sites on the D-I and D-II domains that could be targeted for antibody and vaccine intervention .

How do bispecific antibodies enhance immune responses against viral infections compared to conventional monoclonal antibodies?

Bispecific antibodies offer unique advantages by simultaneously engaging viral antigens and immune effector cells, as demonstrated by the tetravalent bispecific antibody (Bi-Ab32/16) developed for HIV therapy:

• Dual targeting capability: The Bi-Ab32/16 simultaneously targets gp120 on HIV-infected cells and CD16a receptors on NK cells, creating a bridge between the infected cell and the immune effector .

• Enhanced immune recruitment: This bridging function actively recruits NK cells to infected cells that might otherwise evade immune surveillance.

• Polyfunctional immune activation: In vitro studies showed that Bi-Ab32/16 triggered potent, specific, and polyfunctional NK-dependent responses against HIV-infected cells .

• Latent reservoir reduction: The bispecific antibody significantly reduced the latent HIV reservoir after viral reactivation and mediated the clearance of cells harboring intact proviruses in samples from people with HIV .

What challenges arise when targeting latent viral reservoirs with antibody-based therapies?

Targeting latent viral reservoirs presents several complex challenges:

• Limited antigen expression: Latently infected cells typically express minimal viral proteins on their surface, making them "invisible" to antibody recognition. This necessitates combination approaches with latency reversal agents (LRAs) to induce viral gene expression .

• Anatomical sanctuary sites: Viruses often persist in tissues with limited antibody penetration or immune surveillance.

• Immune exhaustion: Sustained stimulation of immune effector cells can lead to their functional exhaustion or depletion, as observed with NK cells in bispecific antibody therapy against HIV .

• Viral diversity: Latent reservoirs often harbor diverse viral sequences, requiring broadly neutralizing antibodies or combinations to achieve adequate coverage.

• Rebound after therapy cessation: Even successful reduction of viral reservoirs may not prevent viral rebound after treatment interruption, as seen in the Bi-Ab32/16 study where NK cell depletion was associated with poor virological control after ART interruption .

What are the optimal techniques for recombinant antibody production and characterization for research applications?

Based on methods described in current antibody research, optimal techniques include:

Production:

• Gene synthesis and optimization: VH and VK/Vλ genes are synthesized with codon optimization for expression efficiency .

• Vector design: Antibody heavy chain and light chain variable gene fragments are cloned into expression vectors containing human IgG1 constant regions using appropriate restriction enzyme sites (Age1/Sal1 for VH; Age1/BsiW1 for VK; Age1/Xho1 for Vλ) .

• Expression system: 293F cells transfected at 1.5 × 10^6 cells/ml using PEI transfection reagent provide high-yield expression of recombinant antibodies .

• Purification process:

  • Initial capture with Protein A agarose

  • Washing with PBS

  • Elution with 0.3 M glycine, pH 2.0 into neutralization buffer (1 M Tris HCl, pH 8.0)

  • Further purification by size exclusion chromatography (SEC)

  • Final dialysis into PBS

Characterization:

• Binding assessment: ELISA assays to evaluate binding to target antigens

• Epitope mapping: Mutational analysis with specific cutoff criteria (<4 angstrom or 4–6 angstrom)

• Functional testing: Cell-based neutralization assays specific to the virus being studied

• Structural analysis: X-ray crystallography or cryo-EM to determine binding interfaces

How can researchers effectively evaluate antibody binding to mutant viral proteins?

The EBV antibody research demonstrates two complementary approaches for evaluating antibody binding to protein mutants:

For mutations with <4 angstrom cutoff:

• Coat plates with 500 ng/well of antibody overnight at 4°C

• Block and wash plates

• Add serially diluted gH/gL mutants in blocking buffer and incubate at 37°C for 1 hour

• Wash and add 1:3000 diluted mouse anti-his antibody

• Detect with 1:5000 diluted goat anti-mouse-HRP antibody

• Develop with substrate and read absorbance at 450 nm

For mutations with 4–6 angstrom cutoff:

• Transfect 293T cells in 24-well plates with 500 ng gH/gL mutated plasmids

• Collect cell supernatants containing secreted gH/gL proteins

• Capture proteins using antibody-coated plates

• Perform antibody binding and detection as in standard ELISA assays

This dual approach allows for comprehensive mapping of antibody epitopes and provides insights into which amino acid residues are critical for antibody binding.

How do findings from neutralizing antibody studies inform vaccine design strategies?

Neutralizing antibody studies provide critical insights for rational vaccine design:

• Identification of vulnerable viral epitopes: Structural analysis of antibody-antigen complexes, such as 1D8 with EBV gH/gL, reveals conserved regions that can be targeted by vaccines. For example, the D-I and D-II domains of gH/gL represent an attractive target for antibody and vaccine intervention against EBV infection .

• Epitope-focused immunogen design: Rather than using whole viral proteins, vaccines can be designed to present specific neutralizing epitopes in their native conformation. This approach could potentially overcome the quantitative disadvantage of less abundant viral proteins like gH/gL compared to more abundant proteins like gp350 .

• Display platforms: Nanoparticles displaying gH/gL have been shown to elicit strong neutralizing antibody responses against EBV infection of both B cells and epithelial cells, demonstrating the potential of multivalent display systems .

• Cross-protection potential: Given the relatively conserved nature of regions like D-I and D-II among herpesviruses, carefully designed immunogens may induce broader cross-neutralizing antibody responses against multiple viral strains .

What safety considerations should researchers address when developing bispecific antibodies for viral infections?

The experience with Bi-Ab32/16 for HIV therapy highlights several important safety considerations:

• Immune cell depletion: Sustained stimulation of immune effector cells (NK cells in the case of Bi-Ab32/16) can lead to their significant decline, compromising long-term efficacy .

• Post-treatment viral control: NK cell depletion was associated with poor virological control after ART interruption in humanized mice, suggesting potential risks when therapy is discontinued .

• Dosing strategies: Careful consideration of dosing regimens may be necessary to prevent overstimulation and depletion of immune effector populations.

• Combinatorial approaches: Pairing bispecific antibodies with agents that support immune cell survival or expansion might counteract depletion effects.

• Biomarker monitoring: Development of biomarkers to monitor immune cell status during therapy could help identify early signs of depletion and guide intervention.

The research underscores the importance of carefully evaluating strategies for sustained immune cell stimulation, particularly during therapy withdrawal periods .

Comparison of Antibody Properties and Applications

The following table summarizes key characteristics of antibodies discussed in the research literature: